RNS Number : 2885Y
Shield Therapeutics PLC
08 May 2019

Shield Therapeutics plc
("Shield" or the "Group")

Appointment of Joint Broker

London, UK, 8 May 2019: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces the appointment of finnCap Ltd as its joint broker with immediate effect.

- Ends -

For further information please contact:

Shield Therapeutics plc www.shieldtherapeutics.com
Carl Sterritt, Chief Executive Officer +44 (0)20 71868500
Tim Watts, Chief Financial Officer

Nominated Advisor and Joint Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden +44 (0)20 74188900

Joint Broker
finnCap Ltd +44 (0)20 72200500
Geoff Nash /Matt Radley/ Alice Lane

Financial PR & IR Advisor
Walbrook PR +44 (0)20 79338780
or shield@walbrookpr.com
Paul McManus / Helen Cresswell +44 (0)7980 541893 / +44 (0)7841 917679

About Shield Therapeutics plc
Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical

needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019. For more information please visit www.shieldtherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

APPBRGDUDDGBGCR